# A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC

> **NCT03904823** · PHASE2 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 58 (estimated)

## Conditions studied

- EGFR-mutant Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** famitinib po
- **DRUG:** HS-10296 po

## Key facts

- **NCT ID:** NCT03904823
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-04-25
- **Primary completion:** 2022-12
- **Final completion:** 2022-12
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2022-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03904823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03904823, "A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03904823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*